Business & Economy · 2 views
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca , a study found.
Summary
A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca , a study found. Full results from a late-stage trial released Saturday show that adding Amgen's immunotherapy Imdelltra to AstraZeneca's Imfinzi drug slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer, a fast-growing disease that has spread beyond the lung where it began.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- Six Flags to Add Seatbelts on Roller Coasters After Rider’s DeathContinue reading
- My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?Continue reading
- My husband wants to sell our $1.5 million home and invest the proceeds. But this is where we raised our kids — and I can’t bear to leave.Continue reading
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economistContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow